Carter's Inc.
BUY: the market is pricing Carter's at a distressed 5.74x TTM P/E despite a four-quarter earnings-beat streak and LTM operating-margin recovery to 10.2%.
At $31.60, CRI is being valued as though FY2025's earnings decline is the permanent state of the business. That conclusion overlooks a material improvement in the underlying run rate. FY2025 EPS fell to $2.59, down 27.4%, and operating margin was 7.9%. The subsequent LTM period shows 10.2% operating margin and 7.4% net margin. The critical distinction is that this is not solely an accounting multiple argument: the latest result beat by 20.9%, and the prior three 2026 quarters also beat estimates. The market has not yet credited the company for a more profitable earnings base.
The case depends first on pricing and margin gains holding through a cautious holiday environment. Second, it depends on FY2025's 1.0% revenue decline stabilizing rather than becoming a renewed volume and promotional cycle. Third, it depends on cash generation being directed conservatively while leverage remains elevated. These are tangible dependencies, not assumptions of a rapid return to the former peak. A recovery to the base-case $57.90 does not require an extreme valuation when the current TTM P/E is 5.74x, although the wide 6.3x peer P/E dispersion means a full peer-average comparison is not a reliable endpoint.
What keeps conviction at Medium is the balance sheet and the market's valid skepticism. Debt is $1.2B and debt/EBITDA is 3.18x LTM, leaving less room for a consumer slowdown than the income statement alone suggests. The stock's 19.56% short interest also reflects a real disagreement over whether margin gains can survive softer demand. Still, the shares are 28.9% below their 52-week high, and the upside case is supported by operational evidence rather than a heroic sales forecast. This is a value-backed turnaround position, not a secular compounder.
Revenue returns to sustained growth, LTM profitability holds, and cash generation supports debt reduction plus a much larger recovery from the current 0.38x TTM sales multiple.
Pricing and margin gains persist, earnings continue to clear a low bar, and the valuation closes part of the gap to the 10.1x peer P/E average.
Cautious holiday demand becomes a broader sales decline, margins retreat from the 10.2% LTM level, and leverage at 3.18x debt/EBITDA prevents a valuation recovery.
Quant call (BUY) diverges from analyst consensus (Sell: 0 buy / 2 hold / 1 sell) — resolve explicitly.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward EPS estimates and formal fiscal guidance were not supplied, so a precise forward P/E cannot be established; the observable valuation is 5.74x TTM earnings, not a verified forward multiple. Earnings power has improved sharply, with 10.2% LTM operating margin versus 7.9% in FY2025, but durable upside requires revenue growth after FY2025's 1.0% decline. Carter's brand, wholesale relationships, and children’s category specialization remain useful today, yet their durability over three to five years is moderate because AI mainly improves demand forecasting, personalization, and inventory planning rather than creating a proprietary consumer moat. AI-enabled discovery can also reduce brand loyalty and intensify digital price comparison, while apparel demand, safety and product-compliance obligations, and a mature North American children’s-apparel TAM keep the long-term stance at HOLD rather than BUY.
- LTM operating margin reached 10.2% through October 3, 2026, up from 7.9% in FY2025, making margin retention the central earnings driver.
- CRI trades at 5.74x TTM P/E and 0.38x TTM P/S, discounts of 43% and 62%, respectively, to the peer averages of 10.1x and 1.0x.
- The four 2026 reported quarters beat Street EPS by 11.8% to 324.8%, including Q3 EPS of $1.03 versus $0.852, a 20.9% beat.
- LTM revenue of $3.0B exceeds FY2025 revenue of $2.9B, and LTM net margin improved to 7.4% from 5.8% in FY2025.
- The October 30, 2026 result delivered $1.03 EPS, 20.9% above the $0.852 estimate, with reported commentary attributing the beat to pricing and margin gains.
- LTM FCF is $0.3B against a $1.2B market capitalization, giving the company material internal cash-generation capacity before considering capital-return choices.
- At $31.60, the shares are 12.8% below the 200-day average of $36.22 and 71.2% below the five-year high of $109.69, so expectations already embed a prolonged deterioration.
- FY2025 revenue fell 1.0% to $2.9B and EPS fell 27.4% to $2.59, showing that the turnaround still needs to prove durable growth rather than just margin repair.
- Total debt was $1.2B as of October 3, 2026, equal to 3.18x LTM debt/EBITDA and a 1.12 debt/equity ratio, which constrains downside resilience.
- Management's November 2 commentary flagged a cautious holiday outlook, and the stock is already down 21.1% over three months, leaving the February report exposed to demand disappointment.
- Short interest is 19.56% of shares, or 6.81M shares and 5.5 days to cover, signaling substantial skepticism that can either pressure a miss or amplify a squeeze.
| Metric | Value | Context |
|---|---|---|
| Share price | $31.60 | Current price, 28.9% below the 52-week high |
| Revenue | $2.9B FY2025 | -1.0% YoY |
| Revenue | $3.0B LTM to 2026-10-03 | Above FY2025 revenue base |
| EPS | $2.59 FY2025 | -27.4% YoY |
| Operating margin | 7.9% FY2025 | Versus 9.0% in prior FY |
| Operating margin | 10.2% LTM to 2026-10-03 | Recovered from FY2025 level |
| P/E | 5.74x TTM | Versus 10.1x five-peer average |
| P/S | 0.38x TTM | Versus 1.0x peer average |
| Debt / EBITDA | 3.18x LTM to 2026-10-03 | Total debt was $1.2B as of 2026-10-03 |
| Free cash flow | $0.3B LTM to 2026-10-03 | Cash generation supports deleveraging capacity |
| Q3 2026 EPS | $1.03 on 2026-10-30 | Versus $0.852 estimate, +20.9% beat |
| Short interest | 19.56% | 6.81M shares, 5.5 days to cover |
A holiday-demand shortfall that reverses the LTM 10.2% operating margin would be especially damaging because CRI carries $1.2B of debt and 3.18x LTM debt/EBITDA.
February 26, 2027 earnings: investors need evidence that the pricing and margin gains behind Q3's $1.03 EPS, a 20.9% beat, can overcome management's cautious holiday stance.
Institutional ownership is concentrated, with the top three institutions holding 94.0%, while insiders own 3.3%. Short interest of 19.56%, equal to 6.81M shares and 5.5 days to cover, creates meaningful squeeze potential if February results validate margin durability, although it also represents an informed bearish constituency. Options gamma is negative within 45 days, with zero gamma at $34.32, 7.69% above spot, which can magnify declines below that level; call and put wall values were not available in usable form.
No product-segment revenue split was provided, preventing a quantified read on brand, channel, or category concentration.
No geographic revenue split was provided; the available financial picture is consolidated, with $3.0B LTM revenue.
Analysis unavailable
The provided 2024 Q4 call is marked stale and contains no usable guidance, margin, cash-flow, or program-timeline commitments, so management cannot be credibly scored against specific promises from that call. The observable record since then is mixed but improving: CRI missed Street EPS by 60.5% in July 2025 and 5.1% in October 2025, after beating by 27.8% and 24.5% in the two prior reports. Execution then improved materially, with each of the four 2026 reports beating expectations, including 324.8% in July and 20.9% in October, alongside operating-margin improvement from 7.9% in FY2025 to 10.2% LTM. Management has earned greater confidence on near-term cost, pricing, and margin delivery, but the lack of supplied historical commitments and the cautious holiday outlook prevent a high-credibility designation on growth.
Carter's protection comes from brand recognition in children's apparel, scale purchasing, and established retail and wholesale distribution, reflected in its ability to generate 10.2% LTM operating margin on $3.0B LTM revenue. Those advantages support sourcing and replenishment economics but do not eliminate consumer switching or promotional pressure. The moat is therefore serviceable today, not widening: AI can improve inventory allocation and personalization, but the same tools are broadly available to rivals and marketplaces.
The supplied LTM data show $0.3B FCF, while the deep-dive cash-flow feed separately reports $0.1B FCF, with $0.0B capex, buybacks, and dividends; the differing FCF figures cannot be reconciled from the supplied bases. The evident priority should be balance-sheet repair given $1.2B total debt as of October 3, 2026 and 3.18x LTM debt/EBITDA, not aggressive shareholder distributions. No announced repurchase, dividend, or acquisition program was provided, so capital-allocation quality remains unproven rather than clearly poor.
CRI is a BUY at Medium conviction for the next 6 to 12 months. The stock is cheap on observable TTM measures, and the four-quarter beat streak plus 10.2% LTM operating margin indicates that the business is healthier than FY2025 results imply. The debt load and cautious holiday commentary prevent High conviction and make the February 26 earnings report decisive. The rating would change to HOLD if margin falls materially from the LTM level or if debt/EBITDA rises above the current 3.18x; it would strengthen if revenue stabilizes while leverage declines.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. CRI rates a BUY at Medium conviction. The shares sit 28.9% below the 52-week high and trade at 0.38x TTM sales, versus peers at 1.0x, while the latest four reported quarters all beat earnings expectations. The valuation discount is justified partly by 3.18x LTM debt/EBITDA and a cautious holiday outlook, but it is too severe if pricing and margin gains sustain the current earnings base.
Investment Thesis
At $31.60, CRI is being valued as though FY2025's earnings decline is the permanent state of the business. That conclusion overlooks a material improvement in the underlying run rate. FY2025 EPS fell to $2.59, down 27.4%, and operating margin was 7.9%. The subsequent LTM period shows 10.2% operating margin and 7.4% net margin. The critical distinction is that this is not solely an accounting multiple argument: the latest result beat by 20.9%, and the prior three 2026 quarters also beat estimates. The market has not yet credited the company for a more profitable earnings base.
The case depends first on pricing and margin gains holding through a cautious holiday environment. Second, it depends on FY2025's 1.0% revenue decline stabilizing rather than becoming a renewed volume and promotional cycle. Third, it depends on cash generation being directed conservatively while leverage remains elevated. These are tangible dependencies, not assumptions of a rapid return to the former peak. A recovery to the base-case $57.90 does not require an extreme valuation when the current TTM P/E is 5.74x, although the wide 6.3x peer P/E dispersion means a full peer-average comparison is not a reliable endpoint.
What keeps conviction at Medium is the balance sheet and the market's valid skepticism. Debt is $1.2B and debt/EBITDA is 3.18x LTM, leaving less room for a consumer slowdown than the income statement alone suggests. The stock's 19.56% short interest also reflects a real disagreement over whether margin gains can survive softer demand. Still, the shares are 28.9% below their 52-week high, and the upside case is supported by operational evidence rather than a heroic sales forecast. This is a value-backed turnaround position, not a secular compounder.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Share price | $31.60 | Current price, 28.9% below the 52-week high |
| Revenue | $2.9B FY2025 | -1.0% YoY |
| Revenue | $3.0B LTM to 2026-10-03 | Above FY2025 revenue base |
| EPS | $2.59 FY2025 | -27.4% YoY |
| Operating margin | 7.9% FY2025 | Versus 9.0% in prior FY |
| Operating margin | 10.2% LTM to 2026-10-03 | Recovered from FY2025 level |
| P/E | 5.74x TTM | Versus 10.1x five-peer average |
| P/S | 0.38x TTM | Versus 1.0x peer average |
| Debt / EBITDA | 3.18x LTM to 2026-10-03 | Total debt was $1.2B as of 2026-10-03 |
| Free cash flow | $0.3B LTM to 2026-10-03 | Cash generation supports deleveraging capacity |
| Q3 2026 EPS | $1.03 on 2026-10-30 | Versus $0.852 estimate, +20.9% beat |
| Short interest | 19.56% | 6.81M shares, 5.5 days to cover |
Financial Strength
Liquidity is adequate on the supplied data, with a 2.78 current ratio as of October 3, 2026, and the business produced $0.3B LTM FCF. The balance sheet is nevertheless the key constraint: $1.2B total debt and 3.18x LTM debt/EBITDA leave the company reliant on sustaining its recent margin recovery. Profitability is moving in the right direction, but the financial profile is best described as recovering rather than fortified.
Competitive Position
Carter's protection comes from brand recognition in children's apparel, scale purchasing, and established retail and wholesale distribution, reflected in its ability to generate 10.2% LTM operating margin on $3.0B LTM revenue. Those advantages support sourcing and replenishment economics but do not eliminate consumer switching or promotional pressure. The moat is therefore serviceable today, not widening: AI can improve inventory allocation and personalization, but the same tools are broadly available to rivals and marketplaces.
Management & Guidance
No numerical FY2027 revenue, margin, EPS, or cash-flow guidance was supplied from the 2026 Q3 call. The available current message is a cautious holiday outlook, despite reported pricing and margin gains that supported Q3 EPS of $1.03 versus $0.852 expected. Management's near-term guidance should be treated as guarded but increasingly credible on costs, because the company beat expectations in all four reported 2026 quarters; it has not yet provided enough disclosed numerical outlook to underwrite a strong revenue acceleration.
Segment Analysis
- Product segments (Not disclosed in supplied data): No product-segment revenue split was provided, preventing a quantified read on brand, channel, or category concentration.
- Geographies (Not disclosed in supplied data): No geographic revenue split was provided; the available financial picture is consolidated, with $3.0B LTM revenue.
Capital Allocation
The supplied LTM data show $0.3B FCF, while the deep-dive cash-flow feed separately reports $0.1B FCF, with $0.0B capex, buybacks, and dividends; the differing FCF figures cannot be reconciled from the supplied bases. The evident priority should be balance-sheet repair given $1.2B total debt as of October 3, 2026 and 3.18x LTM debt/EBITDA, not aggressive shareholder distributions. No announced repurchase, dividend, or acquisition program was provided, so capital-allocation quality remains unproven rather than clearly poor.
Management Execution & Track Record
The provided 2024 Q4 call is marked stale and contains no usable guidance, margin, cash-flow, or program-timeline commitments, so management cannot be credibly scored against specific promises from that call. The observable record since then is mixed but improving: CRI missed Street EPS by 60.5% in July 2025 and 5.1% in October 2025, after beating by 27.8% and 24.5% in the two prior reports. Execution then improved materially, with each of the four 2026 reports beating expectations, including 324.8% in July and 20.9% in October, alongside operating-margin improvement from 7.9% in FY2025 to 10.2% LTM. Management has earned greater confidence on near-term cost, pricing, and margin delivery, but the lack of supplied historical commitments and the cautious holiday outlook prevent a high-credibility designation on growth.
Positioning & Flows
Institutional ownership is concentrated, with the top three institutions holding 94.0%, while insiders own 3.3%. Short interest of 19.56%, equal to 6.81M shares and 5.5 days to cover, creates meaningful squeeze potential if February results validate margin durability, although it also represents an informed bearish constituency. Options gamma is negative within 45 days, with zero gamma at $34.32, 7.69% above spot, which can magnify declines below that level; call and put wall values were not available in usable form.
Bull Case
- LTM revenue of $3.0B exceeds FY2025 revenue of $2.9B, and LTM net margin improved to 7.4% from 5.8% in FY2025.
- The October 30, 2026 result delivered $1.03 EPS, 20.9% above the $0.852 estimate, with reported commentary attributing the beat to pricing and margin gains.
- LTM FCF is $0.3B against a $1.2B market capitalization, giving the company material internal cash-generation capacity before considering capital-return choices.
- At $31.60, the shares are 12.8% below the 200-day average of $36.22 and 71.2% below the five-year high of $109.69, so expectations already embed a prolonged deterioration.
Bear Case
- FY2025 revenue fell 1.0% to $2.9B and EPS fell 27.4% to $2.59, showing that the turnaround still needs to prove durable growth rather than just margin repair.
- Total debt was $1.2B as of October 3, 2026, equal to 3.18x LTM debt/EBITDA and a 1.12 debt/equity ratio, which constrains downside resilience.
- Management's November 2 commentary flagged a cautious holiday outlook, and the stock is already down 21.1% over three months, leaving the February report exposed to demand disappointment.
- Short interest is 19.56% of shares, or 6.81M shares and 5.5 days to cover, signaling substantial skepticism that can either pressure a miss or amplify a squeeze.
Valuation & Price Target
Engine price target $57.9 (+83.2% vs current), Medium confidence.
- P/E Multiple: $64.5 (25% weight)
- P/S Multiple: $81.55 (8% weight)
- Quality-adjusted: $34.13 (20% weight)
- DCF: $117.64 (2% weight)
The BUY rating agrees with the quantitative baseline and its $57.90 target, but conviction remains Medium rather than High. The engine's peer-multiple support is fragile: the five-peer average is 10.1x P/E with exceptionally wide 6.3x dispersion, and several listed peers are not clean apparel comparables. The rating instead rests on the independently observable combination of 5.74x TTM P/E, four consecutive 2026 EPS beats, and LTM margin recovery to 10.2%, offset by 3.18x debt/EBITDA, a cautious holiday outlook, and a 50/100 quality score. The three-firm sell-side view of 0 buy, 2 hold, and 1 sell is low-signal context, not a reason to reject the valuation and earnings evidence.
Risk Assessment
Risk score 45/100 (Moderate). A holiday-demand shortfall that reverses the LTM 10.2% operating margin would be especially damaging because CRI carries $1.2B of debt and 3.18x LTM debt/EBITDA.
The Bottom Line
CRI is a BUY at Medium conviction for the next 6 to 12 months. The stock is cheap on observable TTM measures, and the four-quarter beat streak plus 10.2% LTM operating margin indicates that the business is healthier than FY2025 results imply. The debt load and cautious holiday commentary prevent High conviction and make the February 26 earnings report decisive. The rating would change to HOLD if margin falls materially from the LTM level or if debt/EBITDA rises above the current 3.18x; it would strengthen if revenue stabilizes while leverage declines.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr